
	Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable for delivering a wide range of protein vaccine antigens such as those used in currently marketed influenza hepatitis B and human papilloma virus (HPV) vaccines. Care Capital is the lead investor in the company and its largest shareholder.
